184 related articles for article (PubMed ID: 34008071)
1. Uptake of biosimilar trastuzumab in Denmark compared with other European countries: a comparative study and discussion of factors influencing implementation and uptake of biosimilars.
Azuz S; Newton M; Bartels D; Poulsen BK
Eur J Clin Pharmacol; 2021 Oct; 77(10):1495-1501. PubMed ID: 34008071
[TBL] [Abstract][Full Text] [Related]
2. Postmarket policy considerations for biosimilar oncology drugs.
Renwick MJ; Smolina K; Gladstone EJ; Weymann D; Morgan SG
Lancet Oncol; 2016 Jan; 17(1):e31-8. PubMed ID: 26758759
[TBL] [Abstract][Full Text] [Related]
3. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars.
Jensen TB; Bartels D; Sædder EA; Poulsen BK; Andersen SE; Christensen MMH; Nielsen L; Christensen HR
Eur J Clin Pharmacol; 2020 Jan; 76(1):35-40. PubMed ID: 31677117
[TBL] [Abstract][Full Text] [Related]
4. [Biosimilars in oncology. Focus on SB3 studies.].
Del Re M; Del Mastro L
Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572
[TBL] [Abstract][Full Text] [Related]
5. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
[No Abstract] [Full Text] [Related]
7. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
9. Market diffusion of biosimilars in off-patent biologic drug markets across Europe.
Böhm AK; Steiner IM; Stargardt T
Health Policy; 2023 Jun; 132():104818. PubMed ID: 37086662
[TBL] [Abstract][Full Text] [Related]
10. Policies for biosimilar uptake in Europe: An overview.
Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
[TBL] [Abstract][Full Text] [Related]
11. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
[TBL] [Abstract][Full Text] [Related]
12. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey.
Chapman SR; Fitzpatrick RW; Aladul MI
BMJ Open; 2017 Jun; 7(6):e016730. PubMed ID: 28637743
[TBL] [Abstract][Full Text] [Related]
13. Uptake of rheumatology biosimilars in the absence of forced switching.
Di Giuseppe D; Frisell T; Ernestam S; Forsblad-D'Elia H; Lindqvist E; Lindström U; Sjöwall C; Askling J;
Expert Opin Biol Ther; 2018 May; 18(5):499-504. PubMed ID: 29633865
[TBL] [Abstract][Full Text] [Related]
14. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study.
Dylst P; Vulto A; Simoens S
Pharmacoeconomics; 2014 Jul; 32(7):681-91. PubMed ID: 24803078
[TBL] [Abstract][Full Text] [Related]
15. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
[TBL] [Abstract][Full Text] [Related]
16. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
[TBL] [Abstract][Full Text] [Related]
17. [Trastuzumab and its biosimilars].
Sarosiek T; Morawski P
Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim.
Socal MP; Anderson KE; Sen A; Bai G; Anderson GF
Value Health; 2020 Apr; 23(4):481-486. PubMed ID: 32327165
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects.
Zhu X; Ding Y; Yu Y; Wang M; Zhou W; Wang J; Zhu X; Zhang H; Wang M; Chai K; Zhang X; Luk A; Jiang W; Liu S; Zhang Q
Cancer Chemother Pharmacol; 2021 Mar; 87(3):349-359. PubMed ID: 33169186
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland.
Carl DL; Laube Y; Serra-Burriel M; Naci H; Ludwig WD; Vokinger KN
JAMA Netw Open; 2022 Dec; 5(12):e2244670. PubMed ID: 36459139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
